Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.14
Change (%) Stock is Up 0.27 (4.60%)
Volume1,208,729
Market Cap$224,779,260
Shares Outstanding36,609,000
Data as of 12/26/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
DateTitle 
12/23/14Cytokinetics and Astellas Announce Expansion of Collaboration for Development of CK-2127107 in Spinal Muscular Atrophy and Other Neuromuscular IndicationsPrinter Friendly Version
12/05/14Cytokinetics Announces Presentations Relating to Tirasemtiv and Effects on Respiratory Muscle Function at International Symposium on ALS/MNDPrinter Friendly Version
12/01/14Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MNDPrinter Friendly Version
11/26/14Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare ConferencePrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
Download Documentation 2010 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.